Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
EHA 2024: Highlights in Multiple Myeloma : Episode 2
EHA 2024 Insights: Impact of the IMROZ Study on Newly Diagnosed Multiple Myeloma
Joseph Mikhael, MD, discusses the latest trends and innovations regarding multiple myeloma management.
EP: 1.Latest Trends and Innovations in Multiple Myeloma Management at EHA 2024
Now Viewing
EP: 2.EHA 2024 Insights: Impact of the IMROZ Study on Newly Diagnosed Multiple Myeloma
EP: 3.PERSEUS Trial Findings at EHA 2024
EP: 4.Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024
EP: 5.EHA 2024: Teclistimab in High-Risk Relapsed/Refractory Multiple Myeloma
EP: 6.EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM
EP: 7.Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch
Video content above is prompted by the following:
- Please discuss the data presented at the European Hematology Association 2024 (EHA 2024) Hybrid Congress on the IMROZ study of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) vs VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).
- Please provide your key takeaways from this study. How do the results of this study impact the treatment of patients with transplant-ineligible NDMM?
Related Videos
Related Content
